By Rob Curran
Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease.
The Waltham, Mass., developer of biotech treatments for muscle diseases said its DYNE-101 product candidate, which is currently being tested in an early-stage Phase 1/2 clinical trial, received the fast-track designation, which the agency uses to expedite development of drugs for unmet needs. Dyne noted the fast-track status will make its drug eligible for a rolling review, enabling it to submit sections of the Biologic License Application for review as they are ready, rather than the company needing to complete all development steps before receiving input from the FDA.
Dyne anticipates filing for accelerated approval of the treatment in the first half of 2026.
"[Myotonic dystrophy type 1] is a devastating disease with no approved therapies," said Doug Kerr, chief medical officer of Dyne, in a statement.
Myotonic dystrophy is a genetic condition that causes muscle wasting and other debilitating symptoms.
Shares of Dyne was up 6.2% premarket.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
January 21, 2025 08:05 ET (13:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。